Related Experiment Videos
Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: a comparison with bromocriptine
M De Rosa1, A Colao, A Di Sarno
1Department of Endocrinology and Molecular and Clinical Oncology, Federico II University, Naples, Italy.
European Journal of Endocrinology
|April 16, 1998
Summary
Cabergoline (CAB) and bromocriptine (BRC) treatments effectively normalized prolactin levels in hyperprolactinemic males. Cabergoline demonstrated faster improvements in seminal fluid parameters and sexual function compared to bromocriptine.
Area of Science:
- Endocrinology
- Reproductive Medicine
- Pharmacology
Background:
- Hyperprolactinemia in males is associated with impaired sexual and gonadal function, including reduced libido, erectile dysfunction, and infertility.
- Macroprolactinoma, a common cause of hyperprolactinemia, necessitates effective treatment to restore hormonal balance and reproductive health.
Purpose of the Study:
- To compare the efficacy of chronic cabergoline (CAB) versus bromocriptine (BRC) treatment in improving seminal fluid parameters and sexual/gonadal function in hyperprolactinemic males.
- To assess the impact of these treatments on prolactin (PRL) levels, sperm quality, erectile function, and hormone profiles.
Main Methods:
- A comparative study involving 17 males with macroprolactinoma treated with either CAB (0.5-1.5 mg/week) or BRC (5-15 mg/day) for 6 months.
- Assessment of seminal fluid analysis, nocturnal penile tumescence (NPT), and hormone profiles at baseline and various follow-up intervals.
- Monitoring of serum prolactin (PRL) levels throughout the treatment period.
Main Results:
- Both CAB and BRC significantly reduced serum PRL levels, normalizing them within 6 months.
- Significant improvements in sperm count, motility, morphology, and viability were observed with both treatments.
- Cabergoline treatment led to more rapid and evident improvements in seminal fluid parameters and sexual function, including normalization of erections, compared to bromocriptine.
- Increased serum testosterone and dihydrotestosterone levels were recorded in patients treated with CAB.
Conclusions:
- Cabergoline effectively normalizes prolactin levels and improves gonadal and sexual function in males with prolactinoma, achieving these results earlier than bromocriptine.
- Cabergoline offers good tolerability and excellent patient compliance, making it a favorable treatment option for hyperprolactinemic males.
- Both treatments show efficacy in improving fertility parameters, but cabergoline provides a faster therapeutic response.